News Headlines Article

FDA issues draft guidance on biosimilars
Modern Healthcare

The Food and Drug Administration issued three draft guidance documents on the development of drugs known as biosimilars.

The guidance documents outline some of the scientific (PDF) and quality (PDF) issues with developing biosimilars as well as industry questions about the implementation of the Biologics Price Competition and Innovation Act (PDF), part of the Patient Protection and Affordable Care Act.